Raw data of the charts in Fig 1. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 6. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Raw data of the charts in Fig 2. by Kam Pui Tam (19746865)

“…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”

Synergy scores computed by SynergyFinder. by Kam Pui Tam (19746865)

Viability of additional sLCLs upon treatment of bortezomib and venetoclax. by Kam Pui Tam (19746865)

sLCL 381 and 421 panels were observed by fluorescence microscopy (10X). by Kam Pui Tam (19746865)

Synergistic apoptosis, DNA damage response and inhibition of NF-κB induced by bortezomib/venetoclax was related to the expression of BHRF-1, LMP-1, EBNA-3C and botezomib-induced No... by Kam Pui Tam (19746865)

Apoptosis induced by bortezomib/venetoclax was stronger in sLCL expressing BHRF-1, EBNA-3C, LMP-1 and Noxa. by Kam Pui Tam (19746865)

Apoptosis induced by bortezomib/venetoclax was stronger in sLCL expressing BHRF-1, EBNA-3C, LMP-1 and NOXA. by Kam Pui Tam (19746865)

Pathway enrichment analysis of RNA-seq data illustrating the differentially expressed genes that were induced by bortezomib/venetoclax in pathways related to EBV infection and cell... by Kam Pui Tam (19746865)

Bortezomib/venetoclax suppressed G1-S transition in sLCLs expressing EBNA-3C, LMP-1 and bortezomib-induced Noxa. by Kam Pui Tam (19746865)

MTT assay and isobologram analysis showing the effect of bort/venetoclax on the cell viability of BL2 EBV-negative/WT EBV pair, BL31 EBV-negative/WT EBV pair, sLCL 381, and sLCL 42... by Kam Pui Tam (19746865)

PrimeFlow RNA assay verified that the sLCL 381 cells are EBV-infected B cells. by Kam Pui Tam (19746865)

Effects of bortezomib/venetoclax on the growth suppression of sLCL 381 xenografts in SCID mice. by Kam Pui Tam (19746865)

G1 cell cycle arrest and sub-G1 population induced by bortezomib/venetoclax were stronger in sLCL expressing BHRF-1, EBNA-3C, LMP-1 and NOXA. by Kam Pui Tam (19746865)

Bort/venetoclax promote synergistic cell death through inducing expression of apoptotic and DNA damage response markers as well as inhibitor of NF-κB but suppressed regulators for... by Kam Pui Tam (19746865)

Mean muscle activation patterns across the gait cycle during walking with anteroposterior (AP) forces for <i>A)</i> able-bodied individuals and <i>B)</i> individuals after stroke d... by Sanne Ettema (18786312)

The scatterplot, linear regression equation, 95% confidence band, and <i>p</i>-value for the concentration of arsenic (As) in micrograms per liter (μg/L) versus the concentration o... by Seth H. Frisbie (7821866)

Effects of p-ERK1/2 and p-p38MAPK inhibitors on TNFα-induced occludin expression in hCMEC/D3 cells. by Yawen Ni (3723304)

Univariable and multivariable determinants of increasing (low to medium, or medium to high risk level) or decreasing HIV risk (high to medium, or medium to low risk level) in propo... by Maartje G. J. Basten (11819874)